In Dry Eye, A Variety Of Mechanisms Pursue Established Therapies
Market Snapshot: Kala's Phase III nanoparticle along with Aldeyra's aldehyde trap drug and Ocugen's brimonidine/steroid combo, both in Phase II, are among the candidates pursuing Restasis and Xiidra.
You may also be interested in...
Firm revises second Phase III trial for co-primary endpoints, possibly improving its chances of success for demonstrating efficacy on a sign of dry eye disease. Initial Phase III study missed ocular redness measure.
Company hopes a different formulation of its intracanicular insert of cyclosporin might provide longer duration of drug in the eye and better tear production with it.
Biotech doesn’t shut the door on returning to ophthalmic formulation of the calcineurin inhibitor in dry eye but puts primary focus on oral voclosporin in lupus nephritis, with an FDA approval decision imminent.